56105-19-2

Usage

Uses

Used in Pharmaceutical Industry:
1H-PYRROLO[2,3-B]PYRIDIN-3-YLACETIC ACID is used as an antineoplastic agent for its inhibitory effects on cancer cell growth. It targets specific enzymes and pathways, making it a promising candidate for the development of cancer treatments.
1H-PYRROLO[2,3-B]PYRIDIN-3-YLACETIC ACID is also used as an anti-inflammatory agent for its ability to modulate pathways involved in inflammation, offering potential therapeutic benefits for the treatment of inflammatory diseases.

Upstream product

• 2566-44-1 1-cyclopropylethanol 
• 54120-02-4 2-amino-(1RS)-1-cyclopropylethanol 
• 23936-77-8 formylcyclopropane diethyl acetal 
• 53432-87-4 ethyl 2-cyclopropyl acetate 
• 21908-53-2 mercury(II) oxide 
• 7647-01-0 hydrogenchloride 
• 530133-47-2 methyl 3-cyclopropyl-2,3-epoxypropionate 
• 6542-60-5 2-cyclopropylacetonitrile 
• 34108-21-9 methyl cyclopropylacetate 
• 59226-78-7 1-cyclopropyl-1,1-diethoxyethane 
• 79-37-8 oxalyl dichloride 
• 54120-03-5 1-(cyclopropyl)-2-nitroethanol 

Downstream Products

• 5239-82-7 cyclopropylacetic acid 
• 158743-77-2 diphenylmethyl 7β-<(Z)-2-(2-tert-butoxycarbonylaminothiazol-4-yl)-4-cyclopropyl-2-butenoylamino>-3-cephem-4-carboxylate 
• 894101-39-4 N'-(2-cyclopropylethylidene)hydrazinecarboxylic acid ethyl ester 
• 59-67-6 nicotinic acid 
• 625-37-6 crotonamide 
• 1384970-08-4 C₁₂H₁₂FN₃S 
• 1393123-92-6 (+/-)-3-(4-(2-cyclopropyl-1-(4-(4-(trifluoromethyl)-1H-pyrazol-1-yl)phenoxy)ethyl)benzamido)propanoic acid 
• 1393126-71-0 (+/-)-methyl 4-(2-cyclopropyl-1-(4-(4-(trifluoromethyl)-1H-pyrazol-1-yl)phenoxy)ethyl)benzoate 
• 1393126-72-1 (+/-)-methyl 3-(4-(2-cyclopropyl-1-(4-(4-(trifluoromethyl)-1H-pyrazol-1-yl)phenoxy)ethyl)benzamido)propanoate 
• 1393125-37-5 (+/-)-methyl 4-(2-cyclopropyl-1-hydroxyethyl)benzoate 
• 1610370-38-1 (E)-benzyl 4-cyclopropylbut-2-enoate 
• 1610370-85-8 benzyl 4-(cyclopropylmethyl)-1-(4-((2'-fluoro-5'-methoxy-3-methylbiphenyl-4-yl)methyl)phenyl)-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazole-5-carboxylate 
• 1610370-86-9 (4-(cyclopropylmethyl)-1-(4-((2'-fluoro-5'-methoxy-3-methylbiphenyl-4-yl)methyl)phenyl)-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-5-yl)methanol 

Relevant academic research and scientific papers

Chiral geminal disilyl alkane compound, synthesis method and applications thereof

The present invention discloses a chiral geminal disilyl alkane compound, which is represented by a formula V, wherein * represents a chiral carbon atom in the formula V. The invention discloses a synthesis method of the chiral geminal disilyl alkane compound, wherein the synthesis method comprises: carrying out a reaction in the presence of a reducing agent by using alkyne represented by a formula I, dihydrosilane represented by a formula II and trihydrosilane represented by a formula III as raw materials and using Xantphos-CoBr2 and a chiral CoX2-OIP complex as catalysts under an inert gas to prepare the chiral geminal disilyl alkane compound represented by the formula V. According to the present invention, the method has characteristics of mild reaction condition, simple operation, highatomic economy, no requirement of the addition of any other toxic transition metals (such as ruthenium, rhodium, palladium and the like) salts, high yield and high enantioselectivity, and has great practical value in the synthesis of drugs and materials, wherein the yield is generally 50-85%, and the enantioselectivity is generally 93-99%. The formulas I, II, III and V are defined in the specification.

Racemic gem disilyl alkane compound containing four silicon-hydrogen bonds, and sybthesis method and application of compound

The invention discloses a racemic gem disilyl alkane compound containing four silicon-hydrogen bonds. The compound is as shown in a formula IV. The invention further discloses a synthesis method of the racemic gem disilyl alkane compound. The synthesis method comprises the following step of carrying out a reaction by taking alkyne as shown in a formula I and trihydrosilane as shown in a formula IIas raw materials and taking a chiral CoX-IIP complex as a catalyst in the presence of a reducing agent to obtain the racemic gem disilyl alkane compound containing four silicon-hydrogen bonds, wherein the compound is as shown in the formula IV. The method disclosed by the invention has mild reaction conditions, is simple and convenient to operate and has high atom economy. In addition, the reaction does not need addition of any salts of toxic transition metals (such as ruthenium, rhodium, palladium and the like), and the method has a relatively large practical application value in synthesis of medicines and materials. In addition, the reaction has a medium to excellent yield (51-99%) and high area selectivity (10:1-19:1, most parts larger than 19:1).

COMPOUNDS FOR THE TREATMENT OF PAIN

Provided herein are compounds that are useful in the treatment of pain in a subject.

HETEROARYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE

Provided herein are heteroaryl compounds, for example, a compound of Formula I or IA, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, ameliorating, or preventing one or more symptoms of a disorder, disease, or condition mediated by a casein kinase 1 (CK1), an interleukin-1 receptor associated kinase (IRAK1), or a cyclin-dependent kinase 9 (CDK9). Formula: (I),(IA)

Alkylation Reactions of Azodicarboxylate Esters with 4-Alkyl-1,4-Dihydropyridines under Catalyst-Free Conditions

Introduction of alkyl groups on azodicarboxylate esters is an important method to prepare alkyl amine derivatives. Herein, we report reactions of 4-alkyl-1,4-dihydropyridines as alkylation reagents with di-tert-butyl azodicarboxylate to prepare alkyl amin

Phosphodiesterase inhibitor, and applications thereof

The invention belongs to the technical field of medicine, and more specifically relates to a phosphodiesterase 9 (PDE9) inhibitor represented by formula I, and pharmaceutically acceptable salts, solvates, polymorphic substances, and isomers thereof, and also relates to medicinal preparations, and pharmaceutical compositions of the above compounds, and applications of the medicinal preparations andpharmaceutical compositions. The compounds and the pharmaceutically acceptable salts, solvates, polymorphic substances, and isomers can be used in treatment of phosphodiesterase 9 (PDE9) abnormal expression mediated related diseases.

COMPOUNDS FOR USE IN THE TREATMENT OF INFECTIOUS DISEASES

The present invention relates to compounds of formula (I), wherein R1, R2, R3, R4, R5 and R6 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS

The invention provides compounds of formula (I) or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for suppressing an immune response or treating cancer or a hematologic malignancy using compounds of formula (I).

Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based cyclin-dependent kinase 4 inhibitors: synthesis, biological evaluation and structure-activity relationships

The design, synthesis, and evaluation of novel thieno[2,3-d]pyrimidin-4-yl hydrazone analogues as cyclin-dependent kinase 4 (CDK4) inhibitors are described. In continuing our program aim to search for potent CDK4 inhibitors, the introduction of a thiazole group at the hydrazone part has led to marked enhancement of chemical stability. Furthermore, by focusing on the optimization at the C-4′ position of the thiazole ring and the C-6 position of the thieno[2,3-d]pyrimidine moiety, compound 35 has been identified with efficacy in a xenograft model of HCT116 cells. In this paper, the potency, selectivity profile, and structure-activity relationships of our synthetic compounds are discussed.

CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS

The present invention relates to compounds useful in the treatment of CCR5-related diseases and disorders, for example, useful in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acq